Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Arch Intern Med. 2010 Jul 26;170(14):1228-38. doi: 10.1001/archinternmed.2010.197.

PMID:
20660842
2.

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J.

J Infect Dis. 2010 Feb 1;201(3):318-30. doi: 10.1086/649897.

PMID:
20039804
3.

Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.

Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, Pedersen C, Gerstoft J, Sørensen HT.

HIV Med. 2010 Feb;11(2):130-6. doi: 10.1111/j.1468-1293.2009.00751.x. Epub 2009 Aug 13.

4.

Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy.

Ucciferri C, Falasca K, Vignale F, Di Nicola M, Pizzigallo E, Vecchiet J.

J Med Virol. 2013 May;85(5):755-9. doi: 10.1002/jmv.23543.

PMID:
23508901
5.

Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database.

Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL.

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):245-53. doi: 10.1097/QAI.0b013e31821d33a5.

PMID:
21499115
6.
7.

Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.

Fortuny C, Duiculescu D, Cheng K, Garges HP, Cotton M, Tamarirt DP, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Perger T, Sievers J.

Pediatr Infect Dis J. 2014 Jan;33(1):50-6. doi: 10.1097/INF.0b013e3182a1126a.

8.

Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.

Carosi, Lazzarin, Stellbrink, Moyle, Rugina, Staszewski, Givens, Ross, Granier, Ait-Khaled, Leather, Nichols.

HIV Clin Trials. 2009 Nov-Dec;10(6):356-67. doi: 10.1310/hct1006-356.

PMID:
20133266
9.

Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.

Calza L, Manfredi R, Pocaterra D, Chiodo F.

Int J STD AIDS. 2008 Aug;19(8):541-4. doi: 10.1258/ijsa.2008.007322.

PMID:
18663041
10.

Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.

Merchante N, López-Cortés LF, Delgado-Fernández M, Ríos-Villegas MJ, Márquez-Solero M, Merino D, Pasquau J, García-Figueras C, Martínez-Pérez MA, Omar M, Rivero A, Macías J, Mata R, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Vıricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

AIDS Patient Care STDS. 2011 Jul;25(7):395-402. doi: 10.1089/apc.2011.0109. Epub 2011 Jun 20.

PMID:
21688986
11.

HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals.

Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, Boccara F, Costagliola D; French Hospital Database on HIV (FHDH)–ANRS CO4.

Clin Infect Dis. 2012 Aug;55(4):600-7. Epub 2012 May 18.

PMID:
22610928
12.
13.

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group.

J Antimicrob Chemother. 2009 Aug;64(2):398-410. doi: 10.1093/jac/dkp198. Epub 2009 Jun 10.

PMID:
19515730
14.

Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P.

Clin Infect Dis. 2011 Jul 1;53(1):84-91. doi: 10.1093/cid/cir269.

PMID:
21653308
15.

Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases.

Da Silva B, Tschampa J, Beron J, Fredrick L, Patwardhan M, Zachry W, Woodward WC, Norton M, Nilius A.

Int J Clin Pharmacol Ther. 2012 Jun;50(6):391-402. doi: 10.5414/CP201606.

PMID:
22541744
16.

No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis.

Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):441-7. doi: 10.1097/QAI.0b013e31826f993c.

PMID:
22932321
17.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Bini T, Monforte Ad.

Int J Antimicrob Agents. 2005 Jul;26(1):88-91.

PMID:
15878262
18.

Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.

Blick G, Greiger-Zanlungo P, Gretz S, Han J, Dupree D, Garton T, Yau LH, Wine BC, Pakes GE; Boosting Once-daily Lexiva Delivery with ritonavir 100 mg QD [BOLD100] Study Team.

Int J STD AIDS. 2012 Mar;23(3):e18-22. doi: 10.1258/ijsa.2009.009161.

PMID:
22581890
19.

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.

Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chêne G, Clavel F, Girard PM.

Clin Pharmacol Ther. 2004 Apr;75(4):310-23.

PMID:
15060509
20.

Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?

Sibiude J, Warszawski J, Tubiana R, Dollfus C, Faye A, Rouzioux C, Teglas JP, Ekoukou D, Blanche S, Mandelbrot L.

Clin Infect Dis. 2012 May;54(9):1348-60. doi: 10.1093/cid/cis198. Epub 2012 Mar 28.

PMID:
22460969

Supplemental Content

Support Center